Radioimmunotherapy for B-cell non-Hodgkin lymphoma

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Radioimmunotherapy (RIT) combines the targeting advantage of a monoclonal antibody with the radiosensitivity of non-Hodgkin lymphoma (NHL) cells. There are now two radioimmunoconjugates (RICs) - ibritumomab tiuxetan (Zevalin™) and tositumomab (Bexxar™) - that are approved by the FDA in the US for relapsed low-grade or follicular B-cell NHL. Both agents target the CD20 antigen on B-cell lymphoma cells. In relapsed disease, single doses of RIT produce an 80% overall response rate, with approximately 20% of patients achieving durable responses. RIT is very well tolerated and is delivered on an outpatient basis over 1 week. The only significant toxicity is reversible myelosuppression. Both RIT agents have demonstrated high anti-tumor activity in patients who are refractory to rituximab. Current trials are testing RIT as initial therapy with rituximab maintenance, as adjuvant therapy after chemotherapy, or in high-dose protocols with stem-cell support.

Original languageEnglish (US)
Pages (from-to)655-668
Number of pages14
JournalBest Practice and Research: Clinical Haematology
Volume19
Issue number4
DOIs
StatePublished - Dec 2006

Fingerprint

Radioimmunotherapy
B-Cell Lymphoma
Non-Hodgkin's Lymphoma
CD20 Antigens
Cells
Immunoconjugates
Chemotherapy
Stem cells
Refractory materials
Toxicity
Tumors
Monoclonal Antibodies
Testing
Radiation Tolerance
Outpatients
Stem Cells
Maintenance
ibritumomab tiuxetan
Rituximab
Drug Therapy

Keywords

  • CD20
  • ibritumomab tiuxetan (Zevalin™)
  • NHL
  • radioimmunoconjugate
  • radioimmunotherapy
  • tositumomab (Bexxar™)

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Radioimmunotherapy for B-cell non-Hodgkin lymphoma. / Witzig, Thomas Elmer.

In: Best Practice and Research: Clinical Haematology, Vol. 19, No. 4, 12.2006, p. 655-668.

Research output: Contribution to journalArticle

@article{4f7200af0ecd406fb8b478dfbe38714a,
title = "Radioimmunotherapy for B-cell non-Hodgkin lymphoma",
abstract = "Radioimmunotherapy (RIT) combines the targeting advantage of a monoclonal antibody with the radiosensitivity of non-Hodgkin lymphoma (NHL) cells. There are now two radioimmunoconjugates (RICs) - ibritumomab tiuxetan (Zevalin™) and tositumomab (Bexxar™) - that are approved by the FDA in the US for relapsed low-grade or follicular B-cell NHL. Both agents target the CD20 antigen on B-cell lymphoma cells. In relapsed disease, single doses of RIT produce an 80{\%} overall response rate, with approximately 20{\%} of patients achieving durable responses. RIT is very well tolerated and is delivered on an outpatient basis over 1 week. The only significant toxicity is reversible myelosuppression. Both RIT agents have demonstrated high anti-tumor activity in patients who are refractory to rituximab. Current trials are testing RIT as initial therapy with rituximab maintenance, as adjuvant therapy after chemotherapy, or in high-dose protocols with stem-cell support.",
keywords = "CD20, ibritumomab tiuxetan (Zevalin™), NHL, radioimmunoconjugate, radioimmunotherapy, tositumomab (Bexxar™)",
author = "Witzig, {Thomas Elmer}",
year = "2006",
month = "12",
doi = "10.1016/j.beha.2006.05.002",
language = "English (US)",
volume = "19",
pages = "655--668",
journal = "Best Practice and Research in Clinical Haematology",
issn = "1521-6926",
publisher = "Bailliere Tindall Ltd",
number = "4",

}

TY - JOUR

T1 - Radioimmunotherapy for B-cell non-Hodgkin lymphoma

AU - Witzig, Thomas Elmer

PY - 2006/12

Y1 - 2006/12

N2 - Radioimmunotherapy (RIT) combines the targeting advantage of a monoclonal antibody with the radiosensitivity of non-Hodgkin lymphoma (NHL) cells. There are now two radioimmunoconjugates (RICs) - ibritumomab tiuxetan (Zevalin™) and tositumomab (Bexxar™) - that are approved by the FDA in the US for relapsed low-grade or follicular B-cell NHL. Both agents target the CD20 antigen on B-cell lymphoma cells. In relapsed disease, single doses of RIT produce an 80% overall response rate, with approximately 20% of patients achieving durable responses. RIT is very well tolerated and is delivered on an outpatient basis over 1 week. The only significant toxicity is reversible myelosuppression. Both RIT agents have demonstrated high anti-tumor activity in patients who are refractory to rituximab. Current trials are testing RIT as initial therapy with rituximab maintenance, as adjuvant therapy after chemotherapy, or in high-dose protocols with stem-cell support.

AB - Radioimmunotherapy (RIT) combines the targeting advantage of a monoclonal antibody with the radiosensitivity of non-Hodgkin lymphoma (NHL) cells. There are now two radioimmunoconjugates (RICs) - ibritumomab tiuxetan (Zevalin™) and tositumomab (Bexxar™) - that are approved by the FDA in the US for relapsed low-grade or follicular B-cell NHL. Both agents target the CD20 antigen on B-cell lymphoma cells. In relapsed disease, single doses of RIT produce an 80% overall response rate, with approximately 20% of patients achieving durable responses. RIT is very well tolerated and is delivered on an outpatient basis over 1 week. The only significant toxicity is reversible myelosuppression. Both RIT agents have demonstrated high anti-tumor activity in patients who are refractory to rituximab. Current trials are testing RIT as initial therapy with rituximab maintenance, as adjuvant therapy after chemotherapy, or in high-dose protocols with stem-cell support.

KW - CD20

KW - ibritumomab tiuxetan (Zevalin™)

KW - NHL

KW - radioimmunoconjugate

KW - radioimmunotherapy

KW - tositumomab (Bexxar™)

UR - http://www.scopus.com/inward/record.url?scp=33748713431&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748713431&partnerID=8YFLogxK

U2 - 10.1016/j.beha.2006.05.002

DO - 10.1016/j.beha.2006.05.002

M3 - Article

C2 - 16997175

AN - SCOPUS:33748713431

VL - 19

SP - 655

EP - 668

JO - Best Practice and Research in Clinical Haematology

JF - Best Practice and Research in Clinical Haematology

SN - 1521-6926

IS - 4

ER -